Illumina Ventures

Illumina Ventures operates as an independently managed venture fund in strategic partnership with Illumina, a leader in genomics solutions. The firm focuses on early-stage investments in sectors where genomics can create significant impact, leveraging Illumina's expertise and resources. By collaborating with other prominent institutional and strategic investors, Illumina Ventures aims to enhance the development of companies in diverse fields, including life science research, healthcare, agriculture, environmental science, public safety, and personal wellness. This partnership not only provides financial backing but also facilitates access to cutting-edge knowledge and technology in genomics, positioning the fund to drive innovation in these critical areas.

Arnaud Autret

Principal

Wouter Meuleman

Partner

50 past transactions

Sherlock Biosciences

Series B in 2022
Sherlock Biosciences is an engineering biology company offering unparalleled breadth and versatility for diagnostic solutions. It leverages engineering biology tools, including CRISPR and Synthetic Biology, to create molecular diagnostics that can rapidly deliver accurate results for a vast range of needs in virtually any setting. They combine the diagnostic power of SHERLOCK with that of a second core platform technology, Internal Splint-Pairing Expression Cassette Translation Reaction, or INSPECTRTM, to create diagnostic tools that are simple and easy to use in virtually any setting, and at the same time provide accurate, rapid and affordable results. SheSherlock Biosciences was founded in 2019 and is headquartered in Cambridge, Massachusetts, United States.

Kallyope

Series D in 2022
Kallyope is pioneering the science and understanding of gut and gut-brain biology to create medicines that transform human health. Based in New York City, Kallyope is home to some of the world’s most intrepid scientific minds from the world’s top institutions, working alongside a seasoned team with a proven track record of success in drug discovery and development. Kallyope leverages a unique combination of leading technologies and a foundation of internally-developed capabilities to bring fundamentally new solutions to some of the most pressing unmet needs in human health – from diabetes, obesity, and gut disorders to inflammatory disease, migraine, allergies, and more.

Stilla Technologies

Debt Financing in 2021
Stilla Technologies is a Paris-based European Biotechnology company that focuses on accelerating the development of next-generation genetic tests by providing a ground-breaking and flexible digital PCR (dPCR) solution: the Naica System. Taking advantage of cutting-edge microfluidic innovations, Stilla aims to make dPCR a lab commodity to all Life Sciences areas: research, therapeutics, and all the “omics”.

DNA Script

Series C in 2021
DNA Script is a disruptive DNA synthesis company engineering biology to accelerate breakthroughs in life science and human health. Their revolutionary enzymatic technology powers the world's first benchtop DNA printer, SYNTAX, enabling labs to print their own synthetic oligos for greater workflow control and faster access to results.

RedShift BioAnalytics

Series E in 2021
RedShiftBio provides an infrared technology with advanced data analytics to facilitate better, faster decision making in biopharmaceutical development from discovery to market via the direct measurement of previously undetectable change in protein structural attributes critical to drug product efficacy and quality. It has developed a Microfluidic Modulation Spectroscopy (MMS) platform in response to a customer’s request for a better solution, and rather than repurpose outdated tools and methods designed originally for other applications. They started a new and developed MMS from the ground up specifically with the protein scientist in mind. The company was founded in 2005 and is headquartered in Burlington, Massachusetts.

Walking Fish Therapeutics

Series A in 2021
Walking Fish Therapeutics is developing a platform to harness B cells’ capability to activate the immune system in the treatment of cancer, and to serve as in vivo protein factories that produce replacement proteins for deficiency diseases, regenerative proteins, and engineered antibodies.

Alamar Biosciences

Series B in 2021
Alamar Biosciences develops technologies for the detection and treatment of cancer and other diseases at the earliest possible time. The company was founded in 2018 and is headquartered in Fremont, California.

Genome Medical

Series C in 2021
Genome Medical is a national telegenomics technology, services, and strategy company bringing genomic medicine to everyday care. Through its nationwide network of genetic specialists and an efficient Genome Care DeliveryTM technology platform, we provide expert virtual genetic care for individuals and their families to improve health and well-being. They also help health care providers and their patients navigate the rapidly expanding field of genetics and utilize test results to understand the risk for disease, accelerate disease diagnosis, make informed treatment decisions and lower the cost of care.

NanoCellect Biomedical

Series D in 2021
NanoCellect Biomedical develops and delivers microfluidic-based solutions that are affordable, compact, and easy to use. Its expanding portfolio of instruments and consumables enables biomedical scientists to analyze and sort cells required for drug discovery, single cell-omics, cloning, antibody discovery, and basic research.

LetsGetChecked

Series D in 2021
LetsGetChecked is an at-home health testing platform that connects customers to regulated laboratory testing to better manage and control one's individual health. LetsGetChecked is making healthcare and diagnostics open and patient-led, empowering people to use technology in a simple yet powerful way. This offers consumers greater control over their individual health. LetsGetChecked is headquartered in New York, New York, with tests covering general wellness, sexual health, women's health, and men's health, and is available nationwide, as well as in Canada and Europe.

NanoCellect Biomedical

Series C in 2021
NanoCellect Biomedical develops and delivers microfluidic-based solutions that are affordable, compact, and easy to use. Its expanding portfolio of instruments and consumables enables biomedical scientists to analyze and sort cells required for drug discovery, single cell-omics, cloning, antibody discovery, and basic research.

Delfi Diagnostics

Series A in 2021
Delfi Diagnostics detects cancer early, when it is most curable, using high-precision non-invasive blood tests. It uses artificial intelligence and genome sequencing to detect unique patterns of DNA fragmentation in the blood of patients. The company was founded in 2019 and is based in Baltimore, Maryland.

Rebus Biosystems

Series B in 2020
Rebus Biosystems is a venture-backed Silicon Valley-based life science technology company creating revolutionary tools to enable spatial omics research without compromise. The company’s first instrument, the Rebus Esper, is a fully integrated, automated spatial omics platform that delivers quantitative single molecule, single-cell data with subcellular resolution. Advanced imaging, on-system chemistry, and intuitive software have been combined to provide an end-to-end solution requiring minimal hands-on time. Rebus Biosystems provides all-inclusive assay kits to empower researchers with the resolution, scale and speed of the Rebus Esper for multiple applications. Learn more at www.rebusbio.com.

DNA Script

Series B in 2020
DNA Script is a disruptive DNA synthesis company engineering biology to accelerate breakthroughs in life science and human health. Their revolutionary enzymatic technology powers the world's first benchtop DNA printer, SYNTAX, enabling labs to print their own synthetic oligos for greater workflow control and faster access to results.

Encoded Therapeutics

Series D in 2020
Encoded Therapeutics is a developer of precision gene therapies intended to provide treatment for a broad range of severe genetic disorders. The company's therapy pipeline addresses devastating genetic and acquired disorders spanning multiple disease pathways including neurocircuitry, metabolic disorders, neurodegeneration and cardiovascular disease, enabling medical practitioners to treat patients and improve their lives.

Pattern Bioscience

Series B in 2020
Pattern Bioscience is a privately held in vitro diagnostics company founded in 2016 to help combat the problem of antibiotic resistance. The pattern is developing a next-generation clinical microbiology platform based on its patented phenotypic single-cell technology that can identify pathogens and determine their antibiotic response without the need for traditional time-consuming culture steps. Pattern’s Digital CultureTM technology relies on functional endpoints that encompass all possible resistance mechanisms, resulting in a more comprehensive and reliable diagnosis compared to rapid genotypic tests. The platform will deliver more reliable diagnoses days faster than the current standard of care.

Genome Medical

Series B in 2020
Genome Medical is a national telegenomics technology, services, and strategy company bringing genomic medicine to everyday care. Through its nationwide network of genetic specialists and an efficient Genome Care DeliveryTM technology platform, we provide expert virtual genetic care for individuals and their families to improve health and well-being. They also help health care providers and their patients navigate the rapidly expanding field of genetics and utilize test results to understand the risk for disease, accelerate disease diagnosis, make informed treatment decisions and lower the cost of care.

SQZ Biotech

Series D in 2020
SQZ Biotech is a developer of a cell engineering technology designed to deliver a diverse set of materials into patient cells. It is a privately held company that develops cellular therapies for multiple indications using the proprietary CellSqueeze technology. Through internal research programs and external partnerships, SQZ’s unique cell engineering capabilities are being used to develop a new generation of cell therapies by engineering the immune system both through immune activation and immune suppression for a wide range of clinical challenges.

LetsGetChecked

Series C in 2020
LetsGetChecked is an at-home health testing platform that connects customers to regulated laboratory testing to better manage and control one's individual health. LetsGetChecked is making healthcare and diagnostics open and patient-led, empowering people to use technology in a simple yet powerful way. This offers consumers greater control over their individual health. LetsGetChecked is headquartered in New York, New York, with tests covering general wellness, sexual health, women's health, and men's health, and is available nationwide, as well as in Canada and Europe.

Actym Therapeutics, Inc.

Series A in 2020
Actym Therapeutics, based in Berkeley, CA, is a privately-held biotechnology company focused on discovery and development of novel immuno-oncology therapies to treat cancer. The company has developed an attenuated, microbial-based, immunotherapeutic technology platform called STACT (S. Typhimurium-Attenuated Cancer Therapy). In preclinical studies, STACT specifically enriches in many types of solid tumors and not in healthy tissue. Once there, STACT delivers multiplexed immuno-modulatory payloads directly to tumor-resident immune cells. Many of these payload targets are of significant interest to the biopharmaceutical community but are intractable using conventional approaches due to systemic toxicities after intravenous dosing. Furthermore, STACT has been engineered to deliver payload combinations, which facilitates engagement of multiple biological pathways from a single therapy. In April of 2020, Actym raised $34 million in a Series A financing, co-led by Boehringer-Ingelheim Venture Fund and Panacea Venture Healthcare, with participation from Illumina Ventures, Korea Investment Partners, and JLO Ventures.

Kallyope

Series C in 2020
Kallyope is pioneering the science and understanding of gut and gut-brain biology to create medicines that transform human health. Based in New York City, Kallyope is home to some of the world’s most intrepid scientific minds from the world’s top institutions, working alongside a seasoned team with a proven track record of success in drug discovery and development. Kallyope leverages a unique combination of leading technologies and a foundation of internally-developed capabilities to bring fundamentally new solutions to some of the most pressing unmet needs in human health – from diabetes, obesity, and gut disorders to inflammatory disease, migraine, allergies, and more.

Stilla Technologies

Series B in 2020
Stilla Technologies is a Paris-based European Biotechnology company that focuses on accelerating the development of next-generation genetic tests by providing a ground-breaking and flexible digital PCR (dPCR) solution: the Naica System. Taking advantage of cutting-edge microfluidic innovations, Stilla aims to make dPCR a lab commodity to all Life Sciences areas: research, therapeutics, and all the “omics”.

Fluent BioSciences

Series A in 2020
Fluent Biosciences is a life science "single cell" technology company that offers molecular analysis of cells without the use of complex microfluidic instrumentation. The company’s proprietary platform, Pre-Templated Instant Partitions (PIPseqTM), provides instantaneous self-assembly of individual cells or molecules into millions of uniform partitions for sensitive, unbiased preparation of proteins and nucleic acids for sequencing applications. Fluent's technology expands accessibility of single cell, molecule, or protein analysis to every laboratory, enabling broader market access across all researchers in biotech, pharma, and academic centers.

Ribometrix

Venture Round in 2019
Ribometrix is a platform therapeutics company that discovers small molecule drugs that target functional 3D RNA structures to treat human diseases. Our scientific offices are located in the newly renovated Biolabs Space in Durham, with offices in Chapel Hill and Boston.

Delfi Diagnostics

Venture Round in 2019
Delfi Diagnostics detects cancer early, when it is most curable, using high-precision non-invasive blood tests. It uses artificial intelligence and genome sequencing to detect unique patterns of DNA fragmentation in the blood of patients. The company was founded in 2019 and is based in Baltimore, Maryland.

Cradle Genomics

Series A in 2019
At Cradle Genomics, their mission is to provide knowledge that helps every pregnancy. They're dedicated to the transformation of non-invasive prenatal testing (NIPT) by offering the most comprehensive fetal genetic analysis and pregnancy health screening solutions at the earliest stages of pregnancy. Cradle Genomics is newly formed with their headquarters based in San Diego and additional R&D operations located in Detroit. Cradle tests are based on the genetic analysis of fetal cells that are quickly collected during a first trimester visit with no risk to the mother or developing fetus.

Encoded Therapeutics

Series C in 2019
Encoded Therapeutics is a developer of precision gene therapies intended to provide treatment for a broad range of severe genetic disorders. The company's therapy pipeline addresses devastating genetic and acquired disorders spanning multiple disease pathways including neurocircuitry, metabolic disorders, neurodegeneration and cardiovascular disease, enabling medical practitioners to treat patients and improve their lives.

DNA Script

Series B in 2019
DNA Script is a disruptive DNA synthesis company engineering biology to accelerate breakthroughs in life science and human health. Their revolutionary enzymatic technology powers the world's first benchtop DNA printer, SYNTAX, enabling labs to print their own synthetic oligos for greater workflow control and faster access to results.

LunaPBC

Venture Round in 2019
LunaPBC is a developer of a community-owned genomic and medical research platform intended for health research projects with non-profits and for-profits to drive medical discoveries. The company is a Public Benefit Corporation that enables people to share their health data for medical research for the greater good of the community. Its members also get to share the earnings that come from medical breakthroughs through shared community ownership of the database.

LunaDNA

Venture Round in 2019
Created by co-founders of the $40B DNA sequencing leader Illumina, Luna DNA incentivizes the sharing of health and DNA data for research. LunaDNA rewards people for sharing the data they already own while contributing to medical research and discovery that saves lives. DNA sequencing data has become siloed. As personal DNA sequencing has risen in popularity, the data has become siloed as each company looks to maximize their individual profit from this data. There is currently little incentive for consumers to contribute their DNA and health information to a third party database. There are also multiple privacy, security, and trust issues that limit broad participation. The solution is LunaDNA. LunaDNA is a community owned database that rewards individuals shares in the database and rewards for contributing their health and DNA data. Shares entitle members to a share in the profits from medical research and discoveries. The proceeds flow back to the community like dividends as researchers pay to access the data for discovery.

Kallyope

Series B in 2018
Kallyope is pioneering the science and understanding of gut and gut-brain biology to create medicines that transform human health. Based in New York City, Kallyope is home to some of the world’s most intrepid scientific minds from the world’s top institutions, working alongside a seasoned team with a proven track record of success in drug discovery and development. Kallyope leverages a unique combination of leading technologies and a foundation of internally-developed capabilities to bring fundamentally new solutions to some of the most pressing unmet needs in human health – from diabetes, obesity, and gut disorders to inflammatory disease, migraine, allergies, and more.

Stilla Technologies

Series A in 2018
Stilla Technologies is a Paris-based European Biotechnology company that focuses on accelerating the development of next-generation genetic tests by providing a ground-breaking and flexible digital PCR (dPCR) solution: the Naica System. Taking advantage of cutting-edge microfluidic innovations, Stilla aims to make dPCR a lab commodity to all Life Sciences areas: research, therapeutics, and all the “omics”.

Ribometrix

Series A in 2018
Ribometrix is a platform therapeutics company that discovers small molecule drugs that target functional 3D RNA structures to treat human diseases. Our scientific offices are located in the newly renovated Biolabs Space in Durham, with offices in Chapel Hill and Boston.

SQZ Biotech

Series C in 2018
SQZ Biotech is a developer of a cell engineering technology designed to deliver a diverse set of materials into patient cells. It is a privately held company that develops cellular therapies for multiple indications using the proprietary CellSqueeze technology. Through internal research programs and external partnerships, SQZ’s unique cell engineering capabilities are being used to develop a new generation of cell therapies by engineering the immune system both through immune activation and immune suppression for a wide range of clinical challenges.

LunaDNA

Venture Round in 2018
Created by co-founders of the $40B DNA sequencing leader Illumina, Luna DNA incentivizes the sharing of health and DNA data for research. LunaDNA rewards people for sharing the data they already own while contributing to medical research and discovery that saves lives. DNA sequencing data has become siloed. As personal DNA sequencing has risen in popularity, the data has become siloed as each company looks to maximize their individual profit from this data. There is currently little incentive for consumers to contribute their DNA and health information to a third party database. There are also multiple privacy, security, and trust issues that limit broad participation. The solution is LunaDNA. LunaDNA is a community owned database that rewards individuals shares in the database and rewards for contributing their health and DNA data. Shares entitle members to a share in the profits from medical research and discoveries. The proceeds flow back to the community like dividends as researchers pay to access the data for discovery.

Cernostics

Series A in 2018
Cernostics is a life science company developing new molecular diagnostic tests for the fight against cancer. Most current diagnostic approaches offer a limited view of cancer because they fail to evaluate the tumor as a system composed of multiple cell types, not merely tumor cells. Its patent-protected technology platform, TissueCypher, uniquely analyzes whole slide digital images with multiplexed fluorescence, providing greater information and accuracy than traditional subjective tissue diagnostics.

Kallyope

Series B in 2018
Kallyope is pioneering the science and understanding of gut and gut-brain biology to create medicines that transform human health. Based in New York City, Kallyope is home to some of the world’s most intrepid scientific minds from the world’s top institutions, working alongside a seasoned team with a proven track record of success in drug discovery and development. Kallyope leverages a unique combination of leading technologies and a foundation of internally-developed capabilities to bring fundamentally new solutions to some of the most pressing unmet needs in human health – from diabetes, obesity, and gut disorders to inflammatory disease, migraine, allergies, and more.

NanoCellect Biomedical

Venture Round in 2018
NanoCellect Biomedical develops and delivers microfluidic-based solutions that are affordable, compact, and easy to use. Its expanding portfolio of instruments and consumables enables biomedical scientists to analyze and sort cells required for drug discovery, single cell-omics, cloning, antibody discovery, and basic research.

Genome Medical

Series A in 2018
Genome Medical is a national telegenomics technology, services, and strategy company bringing genomic medicine to everyday care. Through its nationwide network of genetic specialists and an efficient Genome Care DeliveryTM technology platform, we provide expert virtual genetic care for individuals and their families to improve health and well-being. They also help health care providers and their patients navigate the rapidly expanding field of genetics and utilize test results to understand the risk for disease, accelerate disease diagnosis, make informed treatment decisions and lower the cost of care.

LunaDNA

Seed Round in 2017
Created by co-founders of the $40B DNA sequencing leader Illumina, Luna DNA incentivizes the sharing of health and DNA data for research. LunaDNA rewards people for sharing the data they already own while contributing to medical research and discovery that saves lives. DNA sequencing data has become siloed. As personal DNA sequencing has risen in popularity, the data has become siloed as each company looks to maximize their individual profit from this data. There is currently little incentive for consumers to contribute their DNA and health information to a third party database. There are also multiple privacy, security, and trust issues that limit broad participation. The solution is LunaDNA. LunaDNA is a community owned database that rewards individuals shares in the database and rewards for contributing their health and DNA data. Shares entitle members to a share in the profits from medical research and discoveries. The proceeds flow back to the community like dividends as researchers pay to access the data for discovery.

NanoCellect Biomedical

Series B in 2017
NanoCellect Biomedical develops and delivers microfluidic-based solutions that are affordable, compact, and easy to use. Its expanding portfolio of instruments and consumables enables biomedical scientists to analyze and sort cells required for drug discovery, single cell-omics, cloning, antibody discovery, and basic research.

DNA Script

Series A in 2017
DNA Script is a disruptive DNA synthesis company engineering biology to accelerate breakthroughs in life science and human health. Their revolutionary enzymatic technology powers the world's first benchtop DNA printer, SYNTAX, enabling labs to print their own synthetic oligos for greater workflow control and faster access to results.

SerImmune

Series A in 2017
Serimmune is a company that studies immunity to find out how environmental factors affect health and disease. Its universal serology platform utilizes bacterial display peptide library technology and sequencing to broadly profile antibody repertoires and identify antigens and epitopes associated with many diseases all in a single assay.

Genome Medical

Series A in 2017
Genome Medical is a national telegenomics technology, services, and strategy company bringing genomic medicine to everyday care. Through its nationwide network of genetic specialists and an efficient Genome Care DeliveryTM technology platform, we provide expert virtual genetic care for individuals and their families to improve health and well-being. They also help health care providers and their patients navigate the rapidly expanding field of genetics and utilize test results to understand the risk for disease, accelerate disease diagnosis, make informed treatment decisions and lower the cost of care.

Human Longevity

Series B in 2016
Human Longevity (HLI) is the genomic-based, health intelligence company empowering proactive healthcare and enabling a life better lived. HLI combines the largest database of genomic and phenotypic data with machine learning to drive discoveries and revolutionize the practice of medicine. Its business areas include the HLI Health Nucleus, a genomic powered clinical research center that uses whole-genome sequence analysis, advanced clinical imaging, and innovative machine learning, along with curated personal health information to deliver the most complete picture of individual health; HLIQ Whole Genome and HLIQ Oncology. It was founded in 2013 and is headquartered in San Diego, California.

Twist Bioscience

Series D in 2016
Twist Bioscience is a synthetic DNA production for specialty chemical compounds and drug development. At Twist Bioscience Corporation, they work in the service of customers who are changing the world for the better. In fields such as health care, agriculture, industrial chemicals, and data storage, by using our synthetic DNA tools, their customers are developing ways to better lives and improve the sustainability of the planet. They believe that the faster their customers succeed, the better for all of them, and Twist Bioscience is uniquely positioned to help accelerate their efforts. Their innovative silicon-based DNA Synthesis Platform provides precision at a scale that we believe is otherwise unavailable to their customers. their platform technologies overcome inefficiencies and enable cost-effective, rapid, precise, high-throughput synthesis and sequencing, providing both the quality and quantity of the tools they need to rapidly realize the opportunity ahead. Twist Bioscience was founded in 2013 and is headquartered in San Francisco, California.

Desktop Genetics

Venture Round in 2016
Desktop Genetics is an international biotechnology company to helps researchers discover and treat the root genetic causes of human disease. Desktop Genetics is a recognized leader in genome editing technology, staffed by a dedicated team of genome editing experts, bioinformaticians, and data scientists. The company's tools and technologies are used by organizations all over the world. It enables the work of their pharma, biotech, and academic customers working in drug discovery and functional genomics.

Biota Technology

Venture Round in 2016
Biota deploys DNA sequencing and data science to explore the earth’s subsurface. We provide actionable diagnostics to the oil & gas industry for maximizing reservoir economics and reducing environmental impact. Biota delivers multimillion–dollar value with insights into drainage volumes, well connectivity, and engineered completions. Our patented technology has been applied on over 500 wells by a majority of the top producers in US Shale.

Kallyope

Series A in 2015
Kallyope is pioneering the science and understanding of gut and gut-brain biology to create medicines that transform human health. Based in New York City, Kallyope is home to some of the world’s most intrepid scientific minds from the world’s top institutions, working alongside a seasoned team with a proven track record of success in drug discovery and development. Kallyope leverages a unique combination of leading technologies and a foundation of internally-developed capabilities to bring fundamentally new solutions to some of the most pressing unmet needs in human health – from diabetes, obesity, and gut disorders to inflammatory disease, migraine, allergies, and more.

23andMe

Series E in 2015
23andMe is a human genome research company enabling users to study their ancestry, genealogy, and inherited traits. A startup co-founded by Linda Avey and Anne Wojcicki, the wife of Google co-founder Sergey Brin, 23andMe has plans to make the human genome searchable. Brin, along with Google, gave 23andMe $3.9 million as part of a series A in May of 2007. The company was named after the number of chromosome pairs in humans. They aim to help people understand what their genes mean by indexing them and highlighting significant findings. 23andMe allows its clients/users to study their ancestry, genealogy and inherited traits. The company also markets to researchers and scientists, for whom they provide neatly categorized and easily searchable data. One reason the Google investment in 23andMe made sense was that this company could enable the search giant to index another facet of the world's information. With the Biotech and Health Care industries growing rapidly, 23andMe could help Google get and maintain a market hold in these already multi-billion dollar areas.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.